|
Publications 2001
1 Independent risk of mechanical ventilation for AIDS-related Pneumocystis carinii pneumonia associated with bronchoalveolar lavage neutrophilia. Bang D, Emborg J, Elkjaer J, Lundgren JD, and Benfield T
Respir Med. 2001;95(8):661-665. abstract
2 Prognostic markers of short-term mortality in AIDS-associated Pneumocystis carinii pneumonia. Benfield TL, Helweg-Larsen J, Bang D, Junge J, and Lundgren JD
Chest. 2001;119(3):844-851. abstract
3 PCR-RFLP analysis of the DHPS gene for the study of resistance of Pneumocystis carinii to sulpha drugs in patients with co-infection PCP/HIV. Costa MC, Helweg-Larsen J, Antunes F, Lundgren B, Diogo J, and Matos O
J Eukaryot Microbiol.2001;Suppl(148S-149S). abstract
4 Highly active antiretroviral therapy and coronary heart disease: the need for perspective. Egger M, Junghans C, Friis-Moller N, and Lundgren JD.
AIDS. 2001;15Suppl 5(S193-S201). abstract
5 [Diagnosis. Pneumocystis carinii]. Helweg-Larsen J and Lundgren B.
Ugeskr Laeger. 2001;163(4):477-478. abstract
6 Clinical correlation of variations in the internal transcribed spacer regions of rRNA genes in Pneumocystis carinii f.sp. hominis. Helweg-Larsen J, Lee CH, Jin S, Hsueh JY, Benfield TL, Hansen J, Lundgren JD, and Lundgren B.
AIDS. 2001;15(4):451-459. abstract
7 Heterogeneity and compartmentalization of Pneumocystis carinii f. sp. hominis genotypes in autopsy lungs. Helweg-Larsen J, Lundgren B,and Lundgren JD
J Clin Microbiol. 2001;39(10):3789-3792. abstract
8 Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual patient data. Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, Coutinho RA, Eugen-Olsen J, Gallart T, Katzenstein TL, Kostrikis LG, Kuipers H, Louie LG, Mallal SA, Margolick JB, Martinez OP, Meyer L, Michael NL, Operskalski E, Pantaleo G, Rizzardi GP, Schuitemaker H, Sheppard HW, Stewart GJ, Theodorou ID, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zagury JF, and O'Brien TR for the International Meta-Analysis of HIV Host Genetics
Ann Intern Med. 2001;135(9):782-795. abstract
9 The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study. Jensen-Fangel S, Kirk O, Blaxhult A, Gerstoft J, Pedersen C, Black FT, Lundgren JD, and Obel N
HIV Clin Trials. 2001;2(2):122-127. abstract
10 Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviraltherapy. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, Katlama C, Lazzarin A, Skinhoj P, and Barton SE for the EuroSIDA Study Group
Blood. 2001;98(12):3406-3412. abstract
11 Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. Kirk O, Gerstoft J, Pedersen C, Nielsen H, Obel N, Katzenstein TL, Mathiesen L, and Lundgren JD
HIV Med.2001;2(1):43-51. abstract
12 Penicillin as empirical therapy for patients hospitalised with community acquired pneumonia at a Danish hospital. Kirk O, Glenthoj J, Dragsted UB, Helweg-Larsen J, Aru TM, Benfield TL, Jensen K, Vestbo J, and Lundgren JD
Dan Med Bull.2001;48(2):84-88. abstract
13 Clinical outcome among HIV-infected patients starting saquinavir hard gel compared toritonavir or indinavir. Kirk O, Mocroft A., Pradier C, Bruun JN, Hemmer R, Clotet B, Miller V, Viard JP, Phillips AN, Lundgren JD and the EuroSIDA Study Group
AIDS.2001;15(8):999-1008. abstract
14 Adverse effect of the CCR5 promoter -2459A allele on HIV-1 disease progression.
Knudsen TB, Kristiansen TB, Katzenstein TL, and Eugen-Olsen J
J Med Virol.2001;65(3):441-444. abstract
15 A new multiplex PCR strategy for the simultaneous determination of fourgenetic polymorphisms affecting HIV-1 disease progression. Kristiansen TB, Knudsen TB, Ohlendorff S, and Eugen-Olsen J
J Immunol Methods. 2001;252(1-2):147-151. abstract
16 Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, D'Arminio Monforte A, Schneider MM, and Lundgren JD for eight European Study Groups
N Engl J Med.2001;344(3):168-174. abstract
17 When to start and stop? Lundgren JD
HIV Med.2001;2(4):229-230. abstract
18 [Heterosexual transmission of HIV in Denmark in2001. A real risk or a negligible problem?]. Lundgren JD
Ugeskr Laeger.2001;163(42):5811. abstract
19 The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. Mocroft A, Phillips AN, Miller V, Gatell J, van Lunzen J, Parkin JM, Weber R, Roge B, Lazzarin A, and Lundgren JD on behalf of the EuroSIDA Study Group
AIDS.2001;15(2):201-209. abstract
20 HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, and Ledergerber B for the Swiss HIV Cohort, the Frankfurt HIV Clinic Cohort and the EuroSIDA Study Group.
JAMA.2001;286(20):2560-2567. abstract
21 Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, Hermans P, Antunes F, Ledergerber B, Kirk O, Lundgren JD on behalf of the EuroSIDA Study Group
AIDS.2001;15(18):2385-2395. abstract
22 Influence of age on CD4 cell recovery in human immunodeficiency virus- infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, Vetter N, Bruun JN, Johnson M, and Lundgren JD for the EuroSIDA Study Group
J Infect Dis.2001;183(8):1290-1294.abstract
23 An open-label randomized trial to evaluate different therapeutic strategies for combination therapy in HIV-1 infection: Design, rationale and methods of the INITIO trial. The INITIO co-ordination committee, Babiker AG, Darbyshire J, Cooper DA, Hooker MH, Withnall R and Yeni P.
Control Clin Trials. 2001;22(2):160-175 abstract
Updated: 13 Dec 2005
|
|
|
|